1 January 2022

A 2022 Dutch cohort found that 704 of 720 patients, or 98%, continued gender-affirming hormones at follow-up

Name: A 2022 Dutch cohort found that 704 of 720 patients, or 98%, continued gender-affirming hormones at follow-up
Start: 2022-01-01
Location: Europe

A 2022 Dutch cohort found that 704 of 720 patients, or 98%, continued gender-affirming hormones at follow-up.

Source: Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent (PubMed, 1998)

Jurisdiction: Europe

Read the dossier on this country